阿福他酶α不同版本一盒的最新价格公布

Afotalase α is an enzyme replacement therapy drug for hypophosphatasia (HPP), developed by Ruisong Pharmaceuticals in the United States. The price of this drug is relatively high in the international market, with the price of 18mg/0.45mL/box being approximately US$13,205. There are currently no generic drugs on the market. Aftase alfa has not yet been approved in the country, and patients need to purchase it through overseas channels. The drug is injected subcutaneously, and the dose is adjusted based on the patient's age and condition.

The latest prices for a box of different versions of aftase α

The prices vary due to different specifications, and are not yet covered by medical insurance, so patients need to pay for them at their own expense. Below is the latest price information for different specifications.

Price of 18mg/0.45mL specifications

The price of 18mg/0.45mL/box of aftase alpha is approximately US$13,205. It is suitable for adult standard dose treatment and requires 2-3 boxes per month. This specification is a commonly used clinical dose, and patients need to calculate the specific dosage based on their weight.

Price of other specifications

Afotalase α is also available in 28mg/0.7mL, 40mg/mL and 80mg/0.8mL. The price varies depending on the specifications. Among them, the 80mg/0.8mL specification is suitable for patients with larger body weight, but it is prohibited for patients weighing less than 40kg to avoid insufficient efficacy.

The high price of aftase alpha limits its widespread application worldwide, and patients are looking forward to more economical alternative treatment options in the future.

Domestic marketing status of aftase α

As of June 2025, aftase α has not yet been approved for marketing in mainland China, and patients need to obtain the drug through overseas channels.

International Marketing Overview

Aftase α was approved for marketing in the United States in 2015, and was subsequently approved in many countries and regions such as Europe and Japan. The drug has become the standard treatment for hypophosphatasia worldwide.

Domestic Approval Progress

Many domestic medical institutions are conducting clinical research on aftase α to evaluate its efficacy and safety in Chinese patients. These data will support future formal marketing applications for the drug.

With the increasing attention paid to rare diseases in China, aftase alpha is expected to be officially approved in the near future, benefiting more Chinese patients.

Usage and dosage of aftase α

Aftase α needs to be injected subcutaneously. The dosage is adjusted according to the patient's age and condition, and the doctor's instructions must be strictly followed.

Perinatal/infancy-onset HPP dose

The recommended dose is 6 mg/kg per week, which can be subcutaneously injected at 2 mg/kg three times per week or 1 mg/kg six times per week. If efficacy is insufficient, the dose can be increased to 9 mg/kg per week.

Dosage of adolescent-onset HPP

The recommended dose is the same as in infancy, 6 mg/kg per week, divided into injections. Injection site reactions may limit tolerance of frequent injection regimens and require individualized adjustments.

Injection method and storage

Afotalase α needs to be refrigerated at 2-8°C and needs to be taken out of the refrigerator and used within 3 hours before injection. Injection sites should be rotated (abdomen, upper arms, thighs, buttocks) to avoid lipoatrophy.

The use of aftase alfa must be carried out under the guidance of experienced medical professionals. Patients are not allowed to adjust the dosage or injection method by themselves.